Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027

Lyell Immunopharma, Inc.

2026-Q1 EPS reported -$1.10 revenue$2,000

Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
Cash $261M as of March 31, 2026, providing runway into Q3 2027.
PiNACLE trial for ronde-cel in 3L+ LBCL: additional data H2 2026, pivotal data mid-2027, BLA submission 2027 expected.
Phase 3 PiNACLE-H2H (ronde-cel vs standard CAR T) commenced dosing; LYL273 Phase 1 for mCRC at Dose Level 3.
Closed second $50M tranche of private placement at $25.61/share; total $100M; Smital Shah appointed CFO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2026 results: net income net loss of $24.2 million.

Period: the first quarter ended March 31, 2026
Net income: net loss of $24.2 million
Result: reported results

Exact text from the filing

Lyell reported a net loss of $24.2 million for the first quarter ended March 31, 2026, compared to a net loss of $52.2 million for the same period in 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-031269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.